Non-Hodgkin lymphoma in elderly patients: Experience at Taipei Veterans General Hospital

Cancer

Volumn 98, Issue 6, 2003, Pages 1188-1195

  Bai, Li Yuan ^a,b   Yang, Muh Hwa ^a,b   Chiou, Tzeon Jye ^a,b   Liu, Jin Hwang ^a,b   Yen, Chueh Chuan ^a,b   Wang, Wei Shu ^a,b   Hsiao, Liang Tsai ^a,b   Chao, Ta Chung ^a,b   Chen, Po Min ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Anthracycline; Chemotherapy; Elderly; Non Hodgkin lymphoma

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; VINCRISTINE;

AGED; ARTICLE; CANCER INCIDENCE; CANCER INVASION; CANCER SURVIVAL; CORRELATION ANALYSIS; ELDERLY CARE; FEMALE; GENERAL HOSPITAL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHODGKIN LYMPHOMA; POPULATION RISK; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RISK FACTOR; SCORING SYSTEM; SIDE EFFECT; SOLDIER; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TAIWAN;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL RATE; TAIWAN;

EID: 0042418181     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11609     Document Type: Article

References (32)

1. Zheng T, Mayne S, Boyle P, Holford T, Liu W, Flannery J. Epidemiology of non-Hodgkin's lymphoma in Connecticut. Cancer. 1992;70:840-849.
2. Carbone A, Volpe R, Gloghini A, et al. Non-Hodgkin's lymphoma in the elderly. I. Pathologic features at presentation. Cancer. 1990;66:1991-1994.
3. Cuttner J, Wallenstein S, Troy K. Non-Hodgkin's lymphoma in patients 70 years of age or older: factors associated with survival. Leuk Res. 2002;26:447-450.
4. Lichtman SM. Lymphoma in the older patient. Semin Oncol. 1995;22:25-28.
5. Vose JM, Armitage JO, Weisenburger DD, et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol. 1988;6:1838-1844.
6. Solal-Celigny P, Chastang C, Herrera A, et al. Age as the main prognostic factor in adult aggressive non-Hodgkin's lymphoma. Am J Med. 1987;83:1075-1079.
7. Dixon DO, Neilan B, Jones SE, et al. Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol. 1986;4:295-305.
8. Kouroukis CT, Browman GP, Esmail R, Meyer RM. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin's lymphoma: a systematic review. Ann Intern Med. 2002;136:144-152.
9. Greil R. Prognosis and management strategies of lymphatic neoplasias in the elderly. Oncology. 1998;55:189-217.
10. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival - a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol. 1997;15:2945-2953.
11. Sonneveld P, de Ridder M, van der Lelie H, et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol. 1995;13:2530-2539.
12. Tirelli U, Errante D, Van Glabbeke M, et al. CHOP is the standard regimen in patients ≥ 70 years of age with intermediate-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:27-34.
13. Tirelli U, Zagonel V, Errante D, et al. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma. J Clin Oncol. 1992;10:228-236.
14. Young WA, Greco FA, Greer JP, Hainsworth JD. Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide. J Natl Cancer Inst. 1994;86:1346-1347.
15. Aviles A, Nambo MJ, Talavera A, Garcia EL, Huerta-Guzman J, Diaz Maqueo JC. Epirubicin (CEOP-Bleo) versus idarubicin (CIOP-Bleo) in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma: dose escalation studies. Anticancer Drugs. 1997;8:937-942.
16. Aoki S, Tsukada N, Nomoto N, et al. Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res. 1998;17:465-470.
17. De Lena M, Maiello E, Lorusso V, et al. Comparison of CHOP-B vs. CEOP-B in 'poor prognosis' non-Hodgkin's lymphoma. A randomized trial. Med Oncol Tumor Phamacother. 1989;6:163-169.
18. Meyer RM, Browman GP, Samosh ML, et al. Randomized Phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:2386-2393.
19. Cooper IA, Wolf MM, Robertson TI, et al. Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group. J Clin Oncol. 1994;12:769-778.
20. Gordon LI, Harrington D, Andersen J, et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med. 1992;327:1342-1349.
21. Silingardi V, Federico M, Cavanna L, et al. ProMECE-CytaBOM vs MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymphoma. 1995;17:313-320.
22. Jelic S, Milanovic N, Tomasevic Z, Matkovic S, Gavrilovic D. Comparison of two non-anthracycline-containing regimens for elderly patients with diffuse large-cell non-Hodgkin's lymphoma - possible pitfalls in results reporting and interpretation. Neoplasma. 1999;46:394-399.
23. Montserrat E, Garcia-Conde J, Vinolas N, et al. CHOP vs. ProMACE-CytaBOM in the treatment of aggressive non-Hodgkin's lymphoma: long-term results of a multicenter randomized trial. (PETHEMA: Spanish Cooperative Group for the Study of Hematological Malignancies Treatment, Spanish Society of Hematology). Eur J Haematol. 1996;57:377-383.
24. Harris NL, Jaffe ES, Stein H, et al. A revised European-American Classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
25. International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
26. Kouroukis CT, Meyer RM. Treatment strategies in elderly patients with aggressive histology lymphoma. Ann Hematol. 2001;80:B86-B88.
27. Boyle DA, Angert VJ. Lymphoma at the extremes of age. Semin Oncol Nurs. 1998;14:302-311.
28. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood. 1994;83:1165-1173.
29. The Non-Hodgkin's Lymphoma Classification Project. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol. 1997;8:973-978.
30. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
31. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.
32. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.